Global Tuberculosis

$261 million*

Minimum Requirement for American Leadership

 
As an airborne disease, Tuberculosis (TB) presents a unique threat that knows no borders, impacting many countries with long-standing U.S. ties.

Download PDF

Justification for Funding

  • The continued spread of multi-drug-resistant tuberculosis (MDR-TB) is a serious global health security threat.  In FY18, USAID projected to contribute to 120,000 MDR-TB patients initiated on treatment, out of 600,000 in need.
  • An estimated 1 million children are suffering from TB, and TB is among the five leading causes of death for women of reproductive age in low-income countries.
  • Schools are TB transmission hot spots, and an estimated 1.78 million young people develop TB every year.
  • In the 23 priority countries new cases have fallen by 20% since 2000 – more than twice as quickly as countries that do not receive U.S. bilateral TB assistance.
  • New approaches are revolutionizing the field, including new medications for TB and rapid diagnostics.  

Cost of Cuts Below $261 Million

President and Congress Budget Comparison

       Congressional Budget   

       President's Budget Request (Base + OCO)

  • Tuberculosis sickens 10.4 million people a year, and it is now the single biggest infectious disease killer, killing 1.7 million people a year. It is in the interest of the United States that countries rapidly transition to effective TB approaches and end the epidemic.
  • USAID strengthens the capacity of national TB programs, in 23 focus countries, to provide high-quality prevention, diagnosis and treatment services. 53 million lives have been saved from TB 2000-2016, showing an enormous return on investment.
  • With this increase, USAID could boldly accelerate progress, ensuring treatment for 90% of people with TB and 60% of people with drug resistant TB by 2022. This would dramatically boost TB prevention, because once a patient is on effective treatment, the disease rapidly becomes non-infectious.

$400 million

Opportunity to Catalyze American Leadership

 

Justification for Additional Funding

  • Tuberculosis sickens 10.4 million people a year, and it is now the single biggest infectious disease killer, killing 1.7 million people a year. It is in the interest of the United States that countries rapidly transition to effective TB approaches and end the epidemic.
  • USAID strengthens the capacity of national TB programs, in 23 focus countries, to provide high-quality prevention, diagnosis and treatment services. 53 million lives have been saved from TB 2000-2016, showing an enormous return on investment.
  • With this increase, USAID could boldly accelerate progress, ensuring treatment for 90% of people with TB and 60% of people with drug resistant TB by 2022. This would dramatically boost TB prevention, because once a patient is on effective treatment, the disease rapidly becomes non-infectious.

Impact of 50% More Funding

1 out of 3 is the proportion of anti-microbial resistance (AMR) deaths that are attributed to TB.

  • About 40% of people with TB are “missing” and not registered and treated by national health programs. In 2016, USAID provided training in TB for 46,000 health workers, and, with increased funding, this training could be expanded and more patients reached.
  • USAID has already significantly increased case notification, for instance contributing to a 20% increase in the Philippines.
  • USAID could accelerate its work in improving the market for MDR-TB medications and strengthening the emergency warning system for stockouts of drugs. Already, with USAID efforts, the cost of MDR-TB regimens has declined 50% since 2012.

*Enacted FY18 Omnibus Appropriation

For more information, please contact: Soshana Hashmie, shashmie@interaction.org

Choose to Invest:   2018  |  2017  |  2016  |  2015  |  2014  |  2013  |  2012